# TYK Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tyk-medicines

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.tykmedicines.com
- Total disclosed funding: $182M
- Latest round: Series D (Dec 28, 2023)
- Investors on record: 17

## About

Established in 2018 and based in Shanghai, China, TYK Medicines operates as a drug developer that engages in research and developing new tumour drugs. The small molecule drug screening platform has been established in Zhengzhou, and new drug formulation factories are being constructed in Changxing and Shanghai. The chairman of the board, Yusheng Wu, graduated from Iowa State University and worked as a senior chief researcher and project manager at Schering Lough New Drug Research and Development Center. In December 2022, the company was rated as a national high-tech enterprise. In August 2024, it raised HKD 205.7 million in Pre-IPO and listed on the Hong Kong Exchange and Clearing Ltd. 

The company engages in the research and development of tumour drugs, as well as small molecule drug design and screening platforms for targeting therapeutics. The company opened TY-9591, TY-302, and TY-2136b and other product pipelines. The drug is suitable for breast cancer, prostate cancer, solid tumours, etc. TYK Medicines also has a deuterated drug research and development technology platform and a large molecule immunotherapy platform.

The company generates revenue by providing antitumor small molecule drugs and develop drug platforms, treatment platforms, and R&D technology platforms.

The company will use the funding for product research, development and commercialization, acquisitions and investments, and to supplement operating funds.

## Funding rounds

- Series D, Dec 28, 2023, $28M — China International Capital Corporation, Zhejiang Changxing Financial Holding Group, Huiyu Pharmaceutical, AceBridge Capital
- Series C, Jan 7, 2022, $52M — ZUIG Investment, Huge Capital
- Series B, May 24, 2021, $62M — Zheshang Venture Capital, Haibang Venture, Sealand Innovation, Zhejiang Changxing Financial Holding Group, Wenzhou Investment
- Series B, Dec 3, 2020, $40M — Addor Capital, Furong Capital, Riverhead Capital, Sanhhua Hongdao Capital
- Series A, Jan 1, 2019 — Tengyuan Capital
- Series A, May 24, 2018 — BioTrack Capital, Beiwote Medicine Technology

## Investors

- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Beiwote Medicine Technology — Series A
- Tengyuan Capital (https://capitalatlas.ai/funds/tengyuan-capital) — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B
- Furong Capital (https://capitalatlas.ai/funds/furong-capital) — Series B
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series B
- Sanhhua Hongdao Capital (https://capitalatlas.ai/funds/sanhhua-hongdao-capital) — Series B
- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series B
- Haibang Venture — Series B
- Sealand Innovation (https://capitalatlas.ai/funds/sealand-innovation) — Series B
- Zhejiang Changxing Financial Holding Group — Series B, Series D
- Wenzhou Investment (https://capitalatlas.ai/funds/wenzhou-investment) — Series B
- ZUIG Investment (https://capitalatlas.ai/funds/zuig-investment) — Series C
- Huge Capital (https://capitalatlas.ai/funds/huge-capital) — Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series D
- Huiyu Pharmaceutical — Series D
- AceBridge Capital — Series D